摘要
目的探讨单一及联合检测肿瘤标志物对卵巢癌患者的诊断及复发的临床价值。方法选取2010年1月至2017年1月间陕西省宝鸡市陈仓医院收治的49例卵巢癌患者作为卵巢癌组,同期收治的40例其他内科疾病导致腹腔积液女性患者作为对照组,采用酶法检测两组患者血清和腹腔积液的糖类抗原153(CA153)、CA125、癌胚抗原(CEA)和恶性肿瘤特异生长因子(TSGF)的表达水平,比较卵巢癌患者血清及腹水中上述指标表达水平的一致性,筛选诊断多种肿瘤标志物组合模型,并探讨肿瘤标志物组合预测治疗后复发的价值。结果卵巢癌患者的血清和腹水中肿瘤标志物表达水平均高于对照组患者,组间比较,差异均有统计学意义(均P<0.05)。CA125+CEA的ROC曲线下面积最大,预测卵巢癌复发最敏感,差异均无统计学意义(均P>0.05)。结论 CA125、CEA及TSGF是卵巢癌患者临床价值较高的肿瘤标志物,有较高的辅助诊断作用。标志物的组合模型可能可以预测卵巢癌的复发,对患者的预后具有临床参考价值。
Objective To evaluate the significance of single and multiple tumor markers for detection of onset and recurrence of ovarian cancer. Methods A total of 49 patients with ovarian cancer treated at Baoji Chencang District Hospital from January 2010 to January 2017 were selected. Another 40 women with ascites induced by other internal diseases were selected as the control group during the same time period. The expression of CA153,CA125,carcinoembryonic antigen（ CEA） and tumor specific growth factor（ TSGF） were detected. Accordance of the above indesxes expression in serum and ascites were compared.Combination models for multiple tumor markers detection were screened. Significance of combined multiple tumor markers in predicting the popstoperative recurrence was discussed. Results The expression of tumor markers was higher in serum and ascites in patients with ovarian cancer than in the control group（ all P〈0. 05）. CA125 ＋ CEA combined with CA125 ＋ TSGF showed the highest sensitivity and specificity for ovarian cancer. Area under ROC curve was the biggest for CA125 ＋ CEA and it shows the greatest sensitivity for the recurrence of ovarian cancer（ all P〈0. 05）. Conclusion CA125,CEA and TSGF were valuable tumor markers for ovarian cance which is an efficant adjuvant diagnosis method. Combination models for multiple tumor markers can better predict the recurrence of ovarian cancer and shows great clinical inspiration for prognosis.
作者
谭雯
胡彩萍
薛莎莎
余敏
王媛
TAN Wen;HU Cai-ping;XUE Sha-sha;YU Min;WANG Yuan(Department of Gynaecology and Obstetrics,Baoji Chencang District Hospital,Baoji 721300,China;Department of Oncological Medicine,People＇s Hospital of Shaanxi Province,Xi＇an 710068,China;Department of Disease Prevention and Healthcare,Xi＇an 710068,China)
出处
《中国肿瘤临床与康复》
2018年第7期826-829,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
基金
陕西省卫生计生委科研项目(2016D036)
西安市科技局社发攻关项目(2016047SF/YX03(4))
陕西省中医药管理局科研项目(15-JC020)
关键词
卵巢肿瘤
肿瘤标志物
诊断模型
分子预后
Ovarian neoplasms
Tumor markers
Diagnostic model
Molecular prognosis
